An international working group of the World Health Organization (WHO) International Agency for Research on Cancer (IARC) classified three widely prescribed generic pharmaceutical agents—hydrochlorothiazide (HCTZ), voriconazole, and tacrolimus—as Group 1 "carcinogenic to humans." The evaluation was first published as a summary in The Lancet Oncology on November 29, 2024, and the full monograph — Volume 137 of the IARC Monographs — was published online on February 11, 2026, driving a fresh wave of consumer and clinical attention in mid-2026.
The classification is based on sufficient epidemiological evidence in humans linking each compound to specific malignancies:
- Hydrochlorothiazide: Sufficient human evidence for squamous cell carcinoma (SCC) of the skin and cancer of the lip (with limited evidence for basal cell carcinoma, malignant melanoma, Merkel cell carcinoma, and malignant adnexal skin tumors).
- Voriconazole: Sufficient human evidence for squamous cell carcinoma of the skin (supported by strong mechanistic evidence of phototoxicity with UV exposure).
- Tacrolimus: Sufficient human evidence for non-Hodgkin lymphoma (NHL) and post-transplant lymphoproliferative disorder (PTLD) in solid organ transplant recipients (with limited human evidence for leukaemia and cutaneous SCC).
The Group 1 designation for three foundational generic drugs has triggered widespread consumer alarm and clinical inquiries. However, for regulatory affairs professionals, generic labeling teams, pharmacovigilance directors, and Pharmacy and Therapeutics (P&T) committee leaders, the IARC Monograph requires precise context.
IARC operates under a hazard identification framework (answering can a molecule cause cancer under specific exposure conditions?), whereas drug regulators like the U.S. FDA and clinical formularies operate under a risk-benefit assessment framework (evaluating whether the therapeutic benefit outweighs the absolute risk at clinical dosing).
IARC Monograph Volume 137 Classification & Evidence Matrix
│
┌────────────────────────────────┼────────────────────────────────┐
│ │ │
[Hydrochlorothiazide] [Voriconazole] [Tacrolimus]
• Group 1 Carcinogen • Group 1 Carcinogen • Group 1 Carcinogen
• Sufficient: Cutaneous SCC • Sufficient: Cutaneous SCC • Sufficient: NHL & PTLD
and Lip Cancer of the Skin (with UV) in Transplant Recipients
• US Rx Volume: ~31.99M Rx • US NADAC: $1.75/200mg tab • US NADAC: $0.78 generic tab
• US NADAC: $0.012/25mg tab • Azole Antifungal Standard • Prograf Brand: $35.63/tab (~46x)
What did IARC Monograph Volume 137 conclude for each drug?
The IARC working group reviewed pharmacoepidemiological cohorts, nested case-control studies, in vitro genetic assays, and animal bioassays to establish the carcinogenic hazard classifications published in The Lancet Oncology summary of Volume 137 (Cogliano et al., 2024).
Summary of IARC Volume 137 Evidence Tiers
┌──────────────────────┬─────────────────────────────┬──────────────────────────┬───────────────────────────┐
│ Pharmaceutical Agent │ Human Cancer Evidence │ Animal Cancer Evidence │ Mechanistic Evidence │
├──────────────────────┼─────────────────────────────┼──────────────────────────┼───────────────────────────┤
│ Hydrochlorothiazide │ Sufficient: Cutaneous SCC │ Sufficient: hepatocellul. │ Limited (with UV): photo- │
│ │ & Cancer of the Lip │ adenoma/carcinoma (mice),│ sensitization; reactive │
│ │ │ adrenal pheochromocytoma │ oxygen generation │
│ Voriconazole │ Sufficient: Cutaneous SCC │ Inadequate │ Strong (with UV): N-oxide │
│ │ of the Skin │ │ phototoxicity; oxidative │
│ │ │ │ stress; DNA damage │
│ Tacrolimus │ Sufficient: NHL & PTLD │ Sufficient: lymphomas in │ Strong: immunosuppression │
│ │ in transplant recipients │ B6C3F1 mice │ in exposed humans; geno- │
│ │ │ │ toxicity; oxidative stress│
└──────────────────────┴─────────────────────────────┴──────────────────────────┴───────────────────────────┘
1. Hydrochlorothiazide (HCTZ)
Hydrochlorothiazide is a thiazide diuretic that has anchored essential hypertension management globally for over six decades. IARC established:
- Primary Target Malignancies: Squamous cell carcinoma of the skin and cancer of the lip. Nationwide Danish registry cohorts demonstrated a clear dose-response relationship between cumulative HCTZ exposure and cutaneous SCC risk — high cumulative use ($\ge 50,000\text{ mg}$, roughly 5.5 years of 25 mg daily) carried an adjusted odds ratio around 4.0, rising to about 7.4 in the highest stratum ($\ge 200,000\text{ mg}$, roughly two decades of daily use) — with a parallel, somewhat weaker dose-response for lip cancer (ever-use OR about 2.1, rising several-fold at cumulative doses above 100,000 mg).
- Biological Mechanism: HCTZ absorbs ultraviolet A (UVA) light, generating reactive oxygen species (singlet oxygen and hydroxyl radicals) that induce oxidative DNA damage such as 8-hydroxy-2'-deoxyguanosine and lipid peroxidation in sun-exposed epidermal keratinocytes.
- Secondary Cancer Sites: IARC noted limited human evidence for basal cell carcinoma (BCC), melanoma, Merkel cell carcinoma, and malignant adnexal skin tumors.
2. Voriconazole
Voriconazole is a broad-spectrum triazole antifungal indicated for invasive aspergillosis, candidemia, and refractory fungal infections in immunocompromised hosts.
- Primary Target Malignancy: Cutaneous squamous cell carcinoma. Studies across lung, heart, and kidney transplant recipients receiving long-term voriconazole prophylaxis or treatment revealed a significant excess of accelerated, multifocal, and aggressive cutaneous SCCs, often preceded by severe photosensitivity, actinic keratoses, and pseudoporphyria.
- Biological Mechanism: Voriconazole and its N-oxide metabolite absorb UVA radiation, generating singlet oxygen and other reactive species and enhancing UV-induced oxidative stress and DNA damage in human keratinocytes and skin models, with gene-drug interaction data pointing to the phototoxic N-oxide metabolite.
- Rodent Data: The evidence in experimental animals was judged inadequate — consistent with voriconazole acting as a classic photocarcinogen whose oncogenicity requires concurrent actinic light exposure.
3. Tacrolimus
Tacrolimus is a potent macrolide calcineurin inhibitor (CNI) used systemically to prevent allograft rejection in solid organ transplantation and topically for moderate-to-severe atopic dermatitis.
- Primary Target Malignancies: Non-Hodgkin lymphoma and post-transplant lymphoproliferative disorder. Large transplant registry cohorts (including the Scientific Registry of Transplant Recipients, SRTR) established that systemic tacrolimus-based immunosuppression significantly increases the incidence of Epstein-Barr virus (EBV)-driven B-cell lymphoproliferative disorders and systemic lymphomas.
- Biological Mechanism: Tacrolimus binds to intracellular FKBP-12, inhibiting calcineurin phosphatase activity and blocking nuclear factor of activated T-cells (NFAT) dephosphorylation. This cripples CD8+ cytotoxic T-cell surveillance against oncogenic viruses (specifically EBV and Human Papillomavirus) and upregulates transforming growth factor-beta (TGF-$\beta$) and vascular endothelial growth factor (VEGF), promoting tumor angiogenesis and immune evasion.
- Topical Formulations: IARC noted limited evidence in humans for cutaneous malignancies with topical tacrolimus ointment, although systemic absorption in severe dermatologic disease remains a mechanistic factor.
Detailed Pharmacoepidemiological Evidence Base
To understand the empirical rigor underlying the IARC Volume 137 determinations, regulatory affairs and pharmacovigilance teams must examine the key epidemiological registries and statistical hazard ratios across each compound.
Key Pharmacoepidemiological Registries
│
┌─────────────────────────────────┼─────────────────────────────────┐
│ │ │
[Danish Nationwide Registries] [FDA Sentinel System & Kaiser] [SRTR Transplant Database]
• Pottegård / Pedersen et al. • Sentinel Initiative Cohort • Scientific Registry of
(2017/2018) • Confirmed NMSC elevation in Transplant Recipients
• OR 3.98 high use; 7.38 at US hypertensive patients • Markedly elevated PTLD /
>=200,000mg HCTZ (SCC) NHL risk vs population
Danish Registry Data on HCTZ and Cutaneous Malignancies
The most influential evidence evaluated by IARC originated from Danish nationwide health registries conducted by Pottegård, Pedersen, and colleagues:
- Squamous Cell Carcinoma (SCC): In a nationwide case-control study of non-melanoma skin cancer (Pedersen et al., Journal of the American Academy of Dermatology, 2018), high cumulative HCTZ use ($\ge 50,000\text{ mg}$) was associated with an adjusted Odds Ratio (OR) of 3.98 (95% CI: 3.68–4.31) for SCC (versus 1.29 for BCC). In the highest cumulative exposure stratum ($\ge 200,000\text{ mg}$, equivalent to roughly 22 years of 25 mg daily), the adjusted SCC OR rose to 7.38 (95% CI: 6.32–8.60).
- Cancer of the Lip: A nationwide case-control study of lip cancer (Pottegård et al., Journal of Internal Medicine, 2017) found ever-use of HCTZ associated with an adjusted OR of 2.1 (95% CI: 1.7–2.6), with the risk rising roughly seven-fold at cumulative doses $\ge 100,000\text{ mg}$.
- Specificity vs Other Antihypertensives: Crucially, other common antihypertensive drug classes—including ACE inhibitors, angiotensin receptor blockers (ARBs), calcium channel blockers, and potassium-sparing diuretics—showed no consistent association with SCC or lip cancer, supporting substance specificity for HCTZ.
Transplant Cohort Evidence on Voriconazole Photocarcinogenesis
Studies across lung and heart transplant recipients provide consistent evidence regarding voriconazole-associated photocarcinogenesis:
- Lung Transplant Cohort Studies: In transplant cohorts (including Singer et al., American Journal of Transplantation, 2012, and subsequent studies), prolonged voriconazole exposure was associated with an approximately two- to three-fold increase in the risk of developing cutaneous SCC after accounting for age, skin phototype, and immunosuppressive regimen, with gene-drug interaction data pointing to the phototoxic N-oxide metabolite.
- Tumor Aggressiveness: Voriconazole-associated SCCs in transplant recipients show a marked predilection for sun-exposed facial and upper-extremity sites, often multifocal and preceded by photosensitivity reactions, actinic keratoses, and pseudoporphyria — and SCC occurrence in exposed children added to the human evidence base.
Transplant Registry Evidence on Tacrolimus and PTLD / Lymphoma
Data from the Scientific Registry of Transplant Recipients (SRTR) and other transplant registries established:
- Post-Transplant Lymphoproliferative Disorder (PTLD): Tacrolimus-based immunosuppression is associated with a meaningful PTLD incidence — commonly on the order of 1% to 3% in adult kidney and liver recipients and substantially higher in pediatric heart, lung, or intestinal transplant recipients — particularly among EBV-seronegative recipients of EBV-positive donor allografts.
- Non-Hodgkin Lymphoma Risk: NHL risk in solid organ transplant recipients maintained on calcineurin-inhibitor immunosuppression runs roughly an order of magnitude above age-matched general-population baselines in registry analyses, reflecting impaired T-cell control of EBV-driven B-cell proliferation.
Photochemical and Biophysical Mechanisms of Carcinogenesis
The biological mechanisms by which these pharmaceutical molecules drive cellular transformation vary from direct photochemical DNA damage to receptor-mediated immunosuppressive oncogenesis.
Biophysical Pathways to Carcinogenesis
│
┌────────────────────────────────┼────────────────────────────────┐
│ │ │
[HCTZ Phototoxicity] [Voriconazole Photosensitivity] [Tacrolimus Immunosuppression]
• UVA absorption (320-400 nm) • UVA activation of N-oxide • FKBP12-Calcineurin blockade
• Singlet oxygen (1O2) and • Inhibits catalase / SOD • Blunts CD8+ T-cell surveillance
hydroxyl radical formation • Impairs NER DNA repair • Upregulates TGF-b & VEGF
• 8-OHdG DNA strand breaks • Accelerates actinic keratosis • Permissive for EBV/HPV oncogenesis
1. Hydrochlorothiazide Photochemistry
Hydrochlorothiazide contains a chlorine atom and a sulfonamide moiety attached to a benzothiadiazine ring. This chemical structure allows HCTZ to absorb radiation in the UVA spectrum (320–400 nm):
- Excited Triplet State Formation: Absorption of UVA photons excites HCTZ into a reactive triplet state.
- Type I and Type II Photoreactions: The excited molecule transfers energy directly to molecular oxygen, generating singlet oxygen ($^1\text{O}_2$) and transferring electrons to generate superoxide anion ($\text{O}_2^{\bullet-}$) and hydroxyl radicals ($^{\bullet}\text{OH}$).
- DNA Adduct Induction: These reactive oxygen species oxidize guanine bases to form 8-hydroxy-2'-deoxyguanosine (8-OHdG) and allied oxidative lesions in basal keratinocytes, initiating G:C to A:T transition mutations characteristic of UV signature mutagenesis.
2. Voriconazole Phototoxicity
Voriconazole undergoes biotransformation into an active fluorinated N-oxide photoproduct that exhibits strong absorbance in the UVA wavelength range:
- Oxidative Stress & Membrane Peroxidation: UVA excitation of voriconazole photoproducts leads to extensive membrane lipid peroxidation and protein carbonyl formation in epidermal cells.
- Nucleotide Excision Repair (NER) Inhibition: In vitro keratinocyte studies demonstrate that voriconazole directly blunts the enzymatic repair kinetics of UV-induced DNA lesions by downregulating key NER enzymes (including XPA and XPC), creating a compounding synergy with ambient sunlight.
3. Tacrolimus Immunological & Direct Oncogenic Signaling
Tacrolimus exerts its oncogenic hazard through both indirect and direct molecular pathways:
- Calcineurin-NFAT Axis Inhibition: Calcineurin dephosphorylation of NFAT transcription factors is essential for interleukin-2 (IL-2) expression and cytotoxic CD8+ T-cell expansion. Inhibition prevents immunosurveillance against EBV-transformed B-cell clones.
- Direct Pro-Tumor Signaling: Beyond immunosuppression, experimental studies report tacrolimus-driven changes consistent with tumor promotion — including effects on TGF-$\beta$ signaling, angiogenesis, and epithelial-mesenchymal transition (EMT) programs in tumor models — while genotoxicity and oxidative stress were observed in experimental systems per the IARC mechanistic summary.
Comparative Pharmacology Across Drug Classes
To assess whether therapeutic substitution is viable, we compare the pharmacological and safety profiles within each respective drug class.
Diuretic Class Comparison: Thiazides vs Alternatives
Comparative Pharmacology: Diuretic Antihypertensives
┌───────────────────────────┬─────────────┬──────────────┬──────────────┬───────────────────────────────┐
│ Diuretic Agent │ Sub-Class │ NADAC Cost │ Half-Life │ Photosensitivity / Skin CA │
├───────────────────────────┼─────────────┼──────────────┼──────────────┼───────────────────────────────┤
│ Hydrochlorothiazide (HCTZ)│ Thiazide │ $0.012 / tab │ 6–15 hours │ Documented; IARC Group 1 │
│ Chlorthalidone │ Thiazide-like│ $0.089 / tab │ 40–60 hours │ Mild photosensitivity reported│
│ Indapamide 2.5 mg │ Thiazide-like│ $0.110 / tab │ 14–24 hours │ Minimal phototoxic signal │
│ Furosemide 20 mg │ Loop Diuretic│ $0.027 / tab │ 1.5–2 hours │ Low phototoxicity risk │
│ Spironolactone 25 mg │ K-Sparing │ $0.043 / tab │ 1.4 hours │ No phototoxicity signal │
│ Amiloride / HCTZ 5-50 │ Combination │ $0.448 / tab │ 6–15 hours │ HCTZ-dependent phototoxicity │
└───────────────────────────┴─────────────┴──────────────┴──────────────┴───────────────────────────────┘
While chlorthalidone and indapamide are effective thiazide-like substitutes with superior 24-hour pharmacokinetic profiles, they share the sulfonamide core. For patients with active or recurrent squamous cell carcinomas, transitioning away from sulfonamide-containing diuretics toward calcium channel blockers (such as amlodipine) or renin-angiotensin system inhibitors is often the preferred dermatologic strategy.
Azole Antifungal Photosensitivity Spectrum
Comparative Photosensitivity Across Azole Antifungals
┌───────────────────────────┬─────────────┬──────────────┬──────────────┬───────────────────────────────┐
│ Antifungal Agent │ Generation │ NADAC Cost │ UV Absorbance│ Clinical Phototoxicity & SCC │
├───────────────────────────┼─────────────┼──────────────┼──────────────┼───────────────────────────────┤
│ Voriconazole 200 mg │ 2nd Gen │ $1.75 / tab │ High (N-Oxide│ Severe; IARC Group 1 SCC call │
│ Posaconazole DR 100 mg │ 2nd Gen │ $2.17 / tab │ Low │ Rare phototoxicity; alt agent │
│ Isavuconazole (Cresemba) │ 2nd Gen │ Not in NADAC │ Negligible │ Minimal phototoxicity reported│
│ Fluconazole 150 mg │ 1st Gen │ $0.58 / tab │ Zero │ No phototoxicity / No SCC │
│ Itraconazole 100 mg cap │ 1st Gen │ $0.83 / tab │ Low │ Occasional rash; no SCC link │
└───────────────────────────┴─────────────┴──────────────┴──────────────┴───────────────────────────────┘
Note: isavuconazole is a brand-only product absent from the CMS NADAC retail snapshot.
In solid organ and allogeneic stem cell transplant recipients requiring extended antifungal prophylaxis or treatment for invasive mold infections, posaconazole and isavuconazole represent proven alternatives that preserve broad Aspergillus and Mucorales coverage while reducing phototoxic risk.
Calcineurin Inhibitors vs Alternative Immunosuppressive Regimens
Comparative Immunosuppression Regimens in Transplantation
┌───────────────────────────┬─────────────┬──────────────┬──────────────┬───────────────────────────────┐
│ Immunosuppressive Agent │ Drug Class │ NADAC Cost │ PTLD Risk │ Cutaneous Malignancy Risk │
├───────────────────────────┼─────────────┼──────────────┼──────────────┼───────────────────────────────┤
│ Tacrolimus 5 mg (Generic) │ CNI │ $0.78 / tab │ Elevated │ IARC Group 1 (NHL/PTLD) │
│ Prograf 5 mg (Astellas) │ CNI │ $35.63 / tab │ Elevated │ IARC Group 1 (NHL/PTLD) │
│ Cyclosporine Modified │ CNI │ $1.45 / cap │ Elevated │ Long-standing IARC Group 1 │
│ Sirolimus 1 mg │ mTOR Inh │ $0.87 / tab │ Lower │ Anti-neoplastic; reduces SCC │
│ Everolimus 0.5 mg │ mTOR Inh │ ~$3.60-4.00 │ Lower │ Anti-neoplastic; reduces SCC │
│ Belatacept (Nulojix IV) │ Costim Inh │ Provider- │ High in EBV- │ Low cutaneous risk; no CNI tox│
│ │ │ administered │ mismatch │ │
└───────────────────────────┴─────────────┴──────────────┴──────────────┴───────────────────────────────┘
In transplant recipients who develop multiple, accelerated cutaneous squamous cell carcinomas while on tacrolimus, converting from a calcineurin inhibitor to an mTOR inhibitor (such as sirolimus or everolimus) has been shown in prospective randomized trials (including the TUMORAPA study) to roughly halve the rate of secondary skin cancers, at the cost of managing mTOR-specific toxicities.
Quantitative Risk-Benefit Balance: Absolute Risk Perspective
To contextualize the epidemiological data for clinical and formulary leaders, it helps to convert the relative risks into absolute-risk terms:
Hydrochlorothiazide Risk in Absolute Terms
┌──────────────────────────────────────┬──────────────────────────────────────────────────────────┐
│ Input (sourced) │ Implication │
├──────────────────────────────────────┼──────────────────────────────────────────────────────────┤
│ Baseline SCC incidence < 0.1%/yr │ Even a 4-7x relative increase in the highest cumulative │
│ (population estimate, O'Neill 2020) │ exposure strata yields a small annual absolute excess — │
│ │ concentrated in long-duration, high cumulative-dose, │
│ Danish registry ORs: 3.98 (>=50,000 │ sun-exposed patients. │
│ mg); 7.38 (>=200,000 mg) │ The excess is a highly treatable, usually curable skin │
│ │ cancer — while untreated hypertension causes strokes, │
│ Risk concentrated in >=5-20 years │ myocardial infarctions, and heart failure with well- │
│ of cumulative use │ established fatality. │
└──────────────────────────────────────┴──────────────────────────────────────────────────────────┘
The practical read for P&T committees: the oncogenic signal from HCTZ is a long-latency, modest absolute-excess risk that is manageable with photoprotection counseling and skin surveillance, concentrated in patients with heavy cumulative exposure and high UV exposure. It does not approach the immediate cardiovascular harm of leaving hypertension untreated — which is why no regulator or guideline body has suggested withdrawal.
Specialty Formulations & Pediatric Considerations: Topical Tacrolimus
While systemic oral and intravenous tacrolimus carry well-established oncogenic risks in transplant recipients, topical tacrolimus (Protopic 0.03% and 0.1% ointment) occupies a distinct regulatory position:
- The 2006 Pediatric Boxed Warning: In 2006, the FDA mandated a Boxed Warning for topical calcineurin inhibitors (tacrolimus and pimecrolimus) regarding potential long-term malignancy risks, driven primarily by systemic rodent bioassays.
- Longitudinal Pediatric Cohort Findings (e.g., the APPLES Study): Prospective observational cohorts tracking pediatric atopic dermatitis patients treated topically over multiple years have found no statistically significant elevation in lymphoma or cutaneous malignancies compared to general population benchmarks, consistent with minimal systemic bioavailability from intact skin.
- Formulary Placement for Atopic Dermatitis: P&T committees should distinguish topical tacrolimus from systemic transplant therapy, ensuring topical access as a steroid-sparing agent for delicate facial and intertriginous skin.
Public Health & Medicaid Policy: The Sunscreen Benefit Opportunity
Attempting to restrict generic HCTZ through prior authorizations on Medicaid or Medicare formularies creates severe clinical disruption. Because low-income populations suffer disproportionate burdens of uncontrolled hypertension and stroke, forcing non-preferred step-edits leads to immediate prescription abandonment.
Instead of restricting medications, forward-thinking health plans and State Medicaid programs are adopting active photoprotection benefit designs:
- Reimbursing Broad-Spectrum Sunscreens: Adding OTC SPF 30+ sunscreens to covered pharmacy benefits for patients receiving chronic photosensitizing medications (HCTZ, voriconazole, amiodarone, doxycycline).
- Preventative Primary Care Quality Metrics: Payers and provider groups could add annual skin-cancer screening reminders to internal quality dashboards (NCQA has no dedicated HEDIS measure here today) for patients with $>5$ years of thiazide exposure.
Hazard Identification vs Risk Assessment: The Essential Distinction
The public anxiety surrounding IARC Monograph Volume 137 stems largely from a fundamental misunderstanding of IARC's mandate compared to regulatory and clinical decision-making bodies.
IARC Hazard vs Regulatory Risk Framework
│
┌───────────────────────────────┴───────────────────────────────┐
│ │
[IARC Hazard Identification] [FDA / P&T Risk Assessment]
• Question: Can this substance cause • Question: What is the absolute risk
cancer under any exposure condition? at therapeutic dosing vs clinical benefit?
• Exposure Dose: Evaluates biological potential, • Risk-Benefit: Prevents strokes, heart failure,
not clinical safety margin graft rejection, and lethal fungal sepsis
• Group 1 Peers: Solar radiation, tobacco smoke, • Practical Policy: Sunscreen counseling, annual
processed meat, alcohol, tamoxifen, cyclosporine skin exams, and duration monitoring
What IARC Group 1 Actually Means
IARC Group 1 signifies that there is sufficient scientific certainty that a substance can cause cancer in humans. It does not quantify the potency, magnitude, or absolute probability of developing cancer at standard clinical doses:
- Sunlight (solar radiation), alcoholic beverages, processed meats, and ionizing radiation are all classified in IARC Group 1 alongside chemotherapeutic agents like cyclophosphamide and tamoxifen.
- Similarly, immunosuppressive agents like cyclosporine and azathioprine have been classified in IARC Group 1 for decades because profound immunosuppression inevitably impairs anti-tumor immunosurveillance.
For a patient receiving tacrolimus following a heart or kidney transplant, the alternative to calcineurin inhibition is acute allograft rejection and death. For a patient taking HCTZ for hypertension, uncontrolled blood pressure carries an immediate, well-documented risk of stroke, myocardial infarction, and chronic kidney disease that vastly exceeds the modest incremental risk of a treatable, non-melanoma skin cancer over decades of exposure.
How does the IARC call differ from existing FDA label warnings?
A critical task for regulatory and labeling teams is evaluating whether current U.S. Prescribing Information (USPI) adequately reflects the epidemiological findings highlighted by IARC.
Current FDA Label Warnings vs IARC Volume 137 Call
┌──────────────────────┬────────────────────────────┬─────────────────────────────┬───────────────────────────┐
│ Pharmaceutical Agent │ Existing FDA Label Status │ FDA Basis / History │ Gap vs IARC Vol 137 │
├──────────────────────┼────────────────────────────┼─────────────────────────────┼───────────────────────────┤
│ Hydrochlorothiazide │ Section 5: Warnings & Prec.│ Updated 2020–2021 based on │ FDA label notes NMSC; │
│ │ (Non-Melanoma Skin Cancer) │ FDA Sentinel initiative data│ IARC specifically names │
│ │ │ │ SCC and lip cancer │
│ Voriconazole │ Section 5: Warnings & Prec.│ Long-standing warnings for │ FDA label notes SCC and │
│ │ (Photosensitivity & SCC) │ phototoxicity, actinic kerat│ toxic epidermal necrolysis;│
│ │ │ and cutaneous SCC risk │ matches IARC phototoxicity│
│ Tacrolimus (Oral/IV) │ Section 5 & Boxed Warning │ Boxed Warning: Malignancies │ Long-standing boxed │
│ │ (Immunosuppression & PTLD) │ (Lymphoma and skin cancers) │ warning aligns with IARC │
│ Tacrolimus (Topical) │ Boxed Warning: Long-term │ Boxed warning since 2006 for│ IARC noted limited human │
│ │ safety not established │ rare lymphoma/skin cancer │ evidence for topical skin │
└──────────────────────┴────────────────────────────┴─────────────────────────────┴───────────────────────────┘
Hydrochlorothiazide Label Evolution
The FDA CDER division updated the generic and brand hydrochlorothiazide labels (including Microzide and combination formulations) in August 2020 through 2021 following an extensive safety review using the FDA Sentinel System and published Scandinavian epidemiological data.
The current USPI Section 5 (Warnings and Precautions) explicitly instructs clinicians:
"Non-Melanoma Skin Cancer: Instruct patients taking hydrochlorothiazide to protect skin from the sun and undergo regular skin cancer screening."
The main distinction introduced by IARC Monograph Volume 137 is the specific, formal recognition of lip cancer as a distinct sufficient-evidence site and the definitive escalation to Group 1 carcinogen status.
Tacrolimus and Voriconazole Labels
- Tacrolimus (Prograf / generic capsules): Already features a prominent Boxed Warning regarding the increased risk for developing serious infections and malignancies, including lymphomas and skin cancers, secondary to immunosuppression.
- Voriconazole (Vfend / generic tablets): Contains detailed language in Warnings and Precautions advising clinicians to avoid intense or prolonged sunlight exposure, apply broad-spectrum sunscreen, and consider discontinuing voriconazole if premalignant skin lesions or squamous cell carcinomas develop.
For comparative pharmacovigilance reporting across these classes, refer to our detailed analyses on calcineurin inhibitor adverse events in FAERS, azole antifungal adverse events, and diuretic adverse events in FAERS.
Exposure Scale & Drug Acquisition Economics (CMS NADAC)
To understand why removing or drastically restricting these drugs is neither practical nor clinically sound, we examine their prescription volume across the United States and their acquisition pricing in the Centers for Medicare & Medicaid Services (CMS) National Average Drug Acquisition Cost (NADAC) database.
US Prescription Scale & NADAC Unit Pricing
│
┌────────────────────────────────┼────────────────────────────────┐
│ │ │
[Hydrochlorothiazide] [Tacrolimus] [Voriconazole]
• ~31.99M US Rx (2024, Rank #18) • Essential Solid Organ CNI • Gold-Standard Aspergillosis
• ~7.94M Unique US Patients • Generic 5mg: $0.776 / tab • Generic 200mg: $1.747 / tab
• Generic 25mg: $0.012 / tab • Prograf Brand: $35.63 / tab • Generic 50mg: $0.447 / tab
• Annual Cost: ~$4.50 / year • Generic 1mg: $0.171 / tab • Fluconazole 150mg: $0.579
Prescription Exposure: The Enormous HCTZ Footprint
According to ClinCalc DrugStats (derived from the Agency for Healthcare Research and Quality [AHRQ] Medical Expenditure Panel Survey [MEPS]):
- Hydrochlorothiazide Prescription Volume: Approximately 31.99 million prescriptions dispensed in the United States in 2024, ranking as the 18th most commonly prescribed medication nationwide.
- Patient Prevalence: An estimated 7.94 million patients take hydrochlorothiazide either as monotherapy or as part of fixed-dose combination anti-hypertensive therapy (e.g., lisinopril/HCTZ, losartan/HCTZ, valsartan/HCTZ).
CMS NADAC Pricing Benchmark Matrix
The table below outlines per-unit acquisition costs across hydrochlorothiazide, voriconazole, tacrolimus, and clinically relevant therapeutic substitutes:
NADAC Acquisition Pricing for IARC Group 1 Generics & Alternatives
┌──────────────────────────────────────┬─────────────┬──────────────┬──────────────┬───────────────────────────┐
│ Medication & Dosage Strength │ Status │ NADAC Unit $ │ Annual Cost │ Clinical Role / Category │
├──────────────────────────────────────┼─────────────┼──────────────┼──────────────┼───────────────────────────┤
│ Hydrochlorothiazide 25 mg Tablet │ Generic (G) │ $0.01237 / EA│ $4.51 / yr │ Thiazide Diuretic Baseline│
│ Hydrochlorothiazide 12.5 mg Capsule │ Generic (G) │ $0.03032 / EA│ $11.07 / yr │ Low-Dose Thiazide Diuretic│
│ Hydrochlorothiazide 50 mg Tablet │ Generic (G) │ $0.03326 / EA│ $12.14 / yr │ High-Dose Thiazide │
│ Lisinopril-HCTZ 10-12.5 mg Tablet │ Generic (G) │ $0.03068 / EA│ $11.20 / yr │ ACEi + Thiazide Comb. │
│ Lisinopril-HCTZ 20-25 mg Tablet │ Generic (G) │ $0.04281 / EA│ $15.63 / yr │ ACEi + Thiazide Comb. │
│ Losartan-HCTZ 50-12.5 mg Tablet │ Generic (G) │ $0.07615 / EA│ $27.79 / yr │ ARB + Thiazide Comb. │
│ Chlorthalidone 25 mg Tablet │ Generic (G) │ $0.08869 / EA│ $32.37 / yr │ Thiazide-Like Substitute │
│ Chlorthalidone 50 mg Tablet │ Generic (G) │ $0.14532 / EA│ $53.04 / yr │ High-Dose Substitute │
│ Tacrolimus 0.5 mg Capsule │ Generic (G) │ $0.15145 / EA│ $110.56 / yr │ CNI Transplant Baseline │
│ Tacrolimus 1 mg Capsule │ Generic (G) │ $0.17120 / EA│ $124.98 / yr │ CNI Transplant Baseline │
│ Tacrolimus 5 mg Capsule │ Generic (G) │ $0.77611 / EA│ $566.56 / yr │ High-Dose CNI Generic │
│ Prograf 1 mg Capsule (Brand) │ Brand (B) │ $7.13671 / EA│ $5,209 / yr │ Astellas Brand CNI (42x) │
│ Prograf 5 mg Capsule (Brand) │ Brand (B) │ $35.63406 /EA│ $26,013 / yr │ Astellas Brand CNI (46x) │
│ Tacrolimus 0.1% Ointment (Topical) │ Generic (G) │ $0.96208 / GM│ N/A (Topical)│ Topical Atopic Dermatitis │
│ Voriconazole 50 mg Tablet │ Generic (G) │ $0.44691 / EA│ $326.24 / yr │ Azole Antifungal Baseline │
│ Voriconazole 200 mg Tablet │ Generic (G) │ $1.74678 / EA│ $1,275 / yr │ Standard Antifungal Dose │
│ Fluconazole 150 mg Tablet │ Generic (G) │ $0.57907 / EA│ Per-Dose Rx │ Non-Photosensitizing Azole│
│ Cyclosporine Modified 100 mg Cap │ Generic (G) │ $1.44629 / EA│ $1,055 / yr │ Alternative CNI Agent │
└──────────────────────────────────────┴─────────────┴──────────────┴──────────────┴───────────────────────────┘
The Economic & Public Health Reality
The economic data highlights critical trade-offs for health plan policy:
- The Extreme Affordability of HCTZ: At $0.01237 per tablet, a full year of hydrochlorothiazide therapy costs approximately $4.51. Attempting to blanket-switch 8 million patients to patent-protected or more expensive anti-hypertensives would inject hundreds of millions of dollars in net pharmacy costs without demonstrated clinical benefit in overall survival or cardiovascular event reduction.
- Chlorthalidone as an Alternative: Chlorthalidone 25 mg costs $0.08869 per tablet ($32.37/year). While slightly more expensive than HCTZ, chlorthalidone has longer half-life coverage and strong ALLHAT trial evidence. However, chlorthalidone also carries mild photosensitivity properties and higher rates of hypokalemia and hyponatremia.
- The Multi-Source Generic Landscape: As detailed in our review of FDA market exclusivity and the Orange Book, all three agents are off-patent, multi-source generic commodities with dozens of active Abbreviated New Drug Applications (ANDAs).
Action Plan for Generic Manufacturers & Labeling Teams
For regulatory affairs directors and pharmacovigilance teams at generic pharmaceutical manufacturers holding approved ANDAs for HCTZ, voriconazole, or tacrolimus, the IARC Monograph requires proactive regulatory surveillance.
Generic Manufacturer Regulatory Action Roadmap
│
┌─────────────────────────────────┼─────────────────────────────────┐
│ │ │
[Signal Surveillance] [Labeling Synchronization] [Risk Management Updates]
• Monitor FDA CDER Safety • Track Reference Listed Drug • Update Periodic Safety Update
Alerts and MedWatch (RLD) labeling supplements Reports (PSUR / PBRER)
• Analyze FAERS spontaneous • Prepare "Changes Being • Review patient package inserts
cutaneous/lymphoma reports Effected" (CBE-0) filings and Medication Guides
Regulatory Compliance Mandates
- RLD Synchronization under 21 CFR 314.70: Generic manufacturers cannot independently modify core safety warnings without reference to the Reference Listed Drug (RLD) labeling, except via the Changes Being Effected (CBE-0) pathway when responding to an FDA-issued Safety Labeling Change (SLC) mandate. Regulatory affairs teams should closely monitor RLD supplement filings for Microzide (HCTZ), Vfend (voriconazole), and Prograf (tacrolimus).
- Periodic Safety Update Reports (PSUR / PBRER): Pharmacovigilance teams must incorporate IARC Monograph Volume 137 citations and evidence summaries into upcoming global safety reports (PBRERs/PADERs), documenting internal signal detection assessments for secondary cutaneous malignancies and lymphoproliferative disorders.
- Medication Guide & Patient Package Insert Accuracy: Ensure all patient-facing Medication Guides clearly reinforce photoprotective measures (broad-spectrum sunscreen SPF $\ge 30$, protective clothing, UV avoidance) without introducing unauthorized language that could conflict with FDA-approved labeling.
- FDA CDER Safety Review Timelines: Global pharmacovigilance teams should anticipate that when IARC elevates high-volume compounds to Group 1, regulatory agencies (including FDA CDER and EMA PRAC) often initiate internal safety signal evaluations within 6 to 12 months. Generic marketing authorization holders must be prepared to respond rapidly to FDA information requests regarding post-marketing cutaneous adverse events and potential Medication Guide harmonization mandates.
Legal, Tort, and Preemption Landscape
From a pharmaceutical product liability perspective, generic manufacturers are largely protected from failure-to-warn state tort claims by federal preemption under the landmark U.S. Supreme Court rulings in PLIVA, Inc. v. Mensing (2011) and Mutual Pharmaceutical Co. v. Bartlett (2013), which established that generic companies must maintain "sameness" with RLD labeling and cannot independently alter warning text.
However, brand innovators (such as Astellas for Prograf and Pfizer for Vfend) face ongoing duty-to-warn scrutiny under Wyeth v. Levine (2009). If new epidemiological data definitively proves an unaddressed risk, brand manufacturers have a continuing obligation to submit labeling supplements to the FDA under CBE-0 procedures.
International Regulatory Perspectives: EMA, Health Canada, and PMDA
Regulatory responses to the photocarcinogenic and oncogenic signals of these agents have varied across global health authorities:
- European Medicines Agency (EMA PRAC): A 2018-2019 PRAC review of hydrochlorothiazide concluded that the product information (SmPC) for HCTZ-containing medicines across EU member states should be updated to include the risk of non-melanoma skin cancer, with an emphasis on dose-dependent SCC risk and photoprotective counseling.
- Health Canada: Communicated in 2019 the increased risk of non-melanoma skin cancer associated with cumulative HCTZ exposure, recommending awareness of the risk, sun protection, and monitoring for skin changes.
Action Plan for P&T Committees & Formulary Leaders
Pharmacy and Therapeutics (P&T) committees, health plan medical directors, and clinical pharmacists must navigate the clinical and communications challenges created by the IARC Group 1 designation.
P&T Committee Formulary Decision Framework
│
┌────────────────────────────────┼────────────────────────────────┐
│ │ │
[Formulary Placement] [Clinical Protocols] [Patient Counseling]
• Maintain Preferred Tier 1 • Do NOT restrict or step-edit • Sun protection education:
status for HCTZ & CNI generics essential therapies SPF >=30, UV clothing, hats
• Avoid knee-jerk removals • Annual skin exams for • Annual dermatologist checks
• Reject non-evidence PA edits transplant & chronic HCTZ pts for high-risk individuals
Actionable P&T Guidance
- Formulary Retention: Do NOT remove hydrochlorothiazide, voriconazole, or tacrolimus from formularies or impose restrictive prior authorization edits. Abrupt discontinuation of anti-hypertensive therapy precipitates hypertensive emergencies, stroke, and cardiovascular events; stopping tacrolimus causes catastrophic allograft rejection; and withholding voriconazole leads to fatal invasive fungal infections.
- Implement Sun-Protection Clinical Protocols:
- Partner with ambulatory care and cardiology clinical pharmacists to embed automated electronic health record (EHR) reminders at prescription dispensing: "Counsel patient on sun protection (SPF $\ge 30$, hats, UV avoidance) due to photosensitizing properties."
- Encourage routine, annual full-body dermatologic examinations for high-risk patients: individuals with Fitzpatrick skin types I–II, history of actinic keratosis, or cumulative HCTZ exposure exceeding 5 years.
- Transplant Population Surveillance: In solid organ transplant programs, ensure established post-transplant skin cancer screening workflows are rigorously maintained. For transplant recipients developing multiple, high-grade cutaneous SCCs on voriconazole or tacrolimus, multidisciplinary teams should evaluate whether transition to alternative antifungal prophylaxis (e.g., posaconazole, isavuconazole) or an mTOR inhibitor-based immunosuppressive regimen (e.g., sirolimus, everolimus—which possess anti-neoplastic properties) is clinically feasible.
Clinical Substitution Decision Tree & Risk-Stratification Model
To assist clinicians and pharmacy managers when evaluating individual patients with elevated cutaneous or lymphoproliferative risk profiles, we outline a structured clinical substitution decision tree:
Hypertension & Diuretic Patient Risk Model
│
┌────────────────────────────────┴────────────────────────────────┐
│ │
[Standard Risk Hypertensive Patient] [High Cutaneous Malignancy Risk]
• Fitzpatrick Type III-VI • Prior Cutaneous SCC or Lip Cancer
• No history of actinic keratosis • Heavy cumulative HCTZ exposure (>10 yrs)
• Controlled BP on HCTZ ($0.012/tab) • Outdoor occupational UV exposure
• ACTION: Maintain HCTZ + Sun Protection • ACTION: Switch to Chlorthalidone or CCB
Clinical Decision Rules for High-Risk Scenarios
- Prior History of Squamous Cell Carcinoma or Lip Cancer: For patients with a personal history of multiple resected cutaneous SCCs, keratoacanthomas, or actinic cheilitis taking hydrochlorothiazide, clinicians should consider substituting HCTZ with a non-thiazide antihypertensive agent (e.g., amlodipine, lisinopril monotherapy, or losartan) or a thiazide-like agent (chlorthalidone, indapamide), alongside strict dermatologic surveillance.
- Refractory Photosensitivity on Voriconazole: In lung or bone marrow transplant recipients exhibiting severe phototoxicity, actinic erythema, or pseudoporphyria during chronic voriconazole therapy, therapeutic drug monitoring (TDM) should verify that voriconazole trough concentrations are not supratherapeutic ($>5.5\text{ mg/L}$). If phototoxicity persists, transition to isavuconazole (Cresemba) or posaconazole (Noxafil)—which possess significantly lower phototoxic potential—should be executed.
- EBV Mismatch & Tacrolimus Dosing: In high-risk transplant pairings (Donor EBV-positive / Recipient EBV-negative), serial quantitative EBV viral load monitoring by PCR should guide tacrolimus trough target reductions (e.g., targeting 4–7 ng/mL rather than 8–12 ng/mL post-Month 6) to mitigate early PTLD transformation.
Patient Communication & Shared Decision-Making Guide
When patients discover that their daily blood pressure or transplant medication is labeled a "Group 1 Carcinogen," anxiety is inevitable. Clinicians and retail pharmacists should follow a standardized 4-step shared decision-making script:
Patient Communication Protocol
│
┌───────────────────────────────┼───────────────────────────────┐
│ │ │
[Step 1: Reassure & Contextualize] [Step 2: Explain Hazard vs Risk] [Step 3: Actionable Sun Steps]
• Do not stop medication abruptly • Compare to sunlight / alcohol • Apply broad-spectrum SPF 30+
• Emphasize stroke / heart risk • Explain absolute risk math • Wear wide-brim hats & UV shirts
• Highlight proven survival benefit• Clarify organ rejection risk • Schedule annual skin checks
- Step 1: Immediate Safety Reassurance: "Do not stop taking your medication. Stopping your blood pressure or transplant medication suddenly puts you at immediate risk for a stroke, heart attack, or organ rejection, which is far more dangerous than the long-term risk being discussed."
- Step 2: Demystify the IARC Label: "The WHO group classifies anything that can cause cancer under any condition as Group 1—this includes sunlight, processed meat, and alcohol. It does not mean the medication is unsafe when taken as prescribed."
- Step 3: Concrete Action Steps: "The medication makes your skin more sensitive to ultraviolet rays from the sun. The best way to protect yourself is to wear sunscreen (SPF 30 or higher) every day, wear a hat outdoors, and have your skin checked by a doctor once a year."
- Step 4: Clinical Review for High-Risk Individuals: "If you have already had skin cancer removed or spend hours working in direct sunlight, let us review whether an alternative medication is appropriate for your specific health history."
Electronic Health Record (EHR) Clinical Decision Support Toolkit
To translate the IARC Monograph findings into actionable clinical workflows without overwhelming prescribers with alert fatigue, health systems and pharmacy benefit managers can deploy targeted EHR decision support:
EHR Clinical Decision Support (CDS) Rules
┌──────────────────────────────┬─────────────────────────────────────┬────────────────────────────────────────┐
│ Trigger Condition │ CDS Alert Type & Severity │ Recommended Order Set & Clinical Action│
├──────────────────────────────┼─────────────────────────────────────┼────────────────────────────────────────┤
│ New HCTZ Rx in patient with │ Tier 2 Advisory: "Patient has prior │ Provide option to substitute with │
│ documented history of skin CA│ history of cutaneous SCC / NMSC." │ amlodipine, chlorthalidone, or ARB. │
│ Voriconazole Rx > 90 days in │ Tier 2 Periodic Reminder: "Prolonged│ Order dermatology baseline skin check │
│ lung/heart transplant pt │ voriconazole phototoxicity risk." │ and review posaconazole/isavuconazole. │
│ Tacrolimus refill in EBV(-) │ Tier 3 Monitoring Reminder: "Check │ Order quantitative plasma EBV PCR test │
│ pediatric transplant pt │ longitudinal EBV viral load." │ and review CNI trough target levels. │
│ Any HCTZ / Voriconazole Rx │ Patient Discharge / Aux Label: │ Auto-print patient educational sheet │
│ at outpatient dispensing │ "Photosensitizing medication." │ on daily broad-spectrum SPF 30+ use. │
└──────────────────────────────┴─────────────────────────────────────┴────────────────────────────────────────┘
Pharmacovigilance Signal Detection in FAERS
In global pharmacovigilance operations, safety epidemiologists also track spontaneous reporting databases—such as the FDA Adverse Event Reporting System (FAERS) and the WHO's VigiBase—for disproportionality signals around these three drugs. Two cautions matter for teams deciding how much weight to give that line of evidence:
- Spontaneous reports are not incidence data and do not establish causality. FAERS case counts for skin cancers and lymphoproliferative disorders among HCTZ, voriconazole, and tacrolimus reporters reflect reporting behavior as much as biology — and oncology outcomes with long latency are notoriously under-reported in spontaneous systems. Use them for signal detection and case-series follow-up, not for quantifying risk.
- The structured epidemiology is the evidence base that moved IARC. The Group 1 determinations rest on registry and cohort studies with comparators, dose-response gradients, and mechanistic triangulation — the standard a hazard classification requires.
For drug-class context on spontaneous adverse-event reporting patterns across these therapeutic areas, see our data-driven analyses of calcineurin inhibitor adverse events in FAERS, azole antifungal adverse events, and diuretic adverse events.
The Arithmetic of Restricting a $4.51-Per-Year Drug
The verified acquisition costs make the futility of restrictive HCTZ policies easy to see with simple, transparent arithmetic (all unit prices from the CMS NADAC 2026-07-24 snapshot):
- A year of HCTZ 25 mg costs about $4.51 ($0.01237 per tablet x 365 days) — among the cheapest drugs in the entire U.S. formulary system.
- The nearest thiazide-like substitute, chlorthalidone 25 mg, costs $32.37 per year ($0.08869 per tablet) — roughly 7x more — while carrying its own photosensitivity considerations and higher rates of electrolyte disturbances.
- Every dollar "saved" by restricting HCTZ is spent several times over on pharmacy benefit administrative review, dispensing disruptions, adherence breaks, and follow-up visits — before counting any downstream cardiovascular events from interrupted antihypertensive therapy.
In other words: a restriction policy targets one of the highest-value, lowest-cost therapies in medicine in response to a long-latency, manageable photocarcinogenicity signal. The rational responses are counseling and surveillance protocols, not formulary removal — the approach every regulator that has examined this signal (EMA, Health Canada, FDA label updates) has taken.
5-Pillar Executive Action Checklist for Health Plan Leaders
To operationalize the clinical and economic recommendations of this analysis, Chief Medical Officers, Pharmacy Directors, and Quality Leadership should execute a 5-pillar action checklist:
Executive 5-Pillar Operational Checklist
┌──────────────────────────────┬──────────────────┬───────────────────────────────────────────────────────────┐
│ Functional Domain │ Responsible Team │ Core Deliverable & Operational Target │
├──────────────────────────────┼──────────────────┼───────────────────────────────────────────────────────────┤
│ 1. Formulary Access │ P&T Committee │ Affirm Tier 1 Preferred Generic status for HCTZ, │
│ │ │ tacrolimus, and voriconazole without prior authorization. │
│ 2. Point-of-Care CDS Alerts │ Health IT / CMIO │ Implement non-interruptive EHR clinical reminders │
│ │ │ advising broad-spectrum sunscreen and UV protection. │
│ 3. Transplant Surveillance │ Solid Organ Team │ Standardize annual full-body dermatologic exams and │
│ │ │ serial quantitative EBV PCR monitoring protocols. │
│ 4. Antifungal Duration Guard │ Antimicrobial St.│ Establish 90-day review gates for chronic voriconazole to │
│ │ │ assess transition to isavuconazole or posaconazole. │
│ 5. Member Communications │ Pharmacy Care │ Deploy patient-facing educational materials emphasizing │
│ │ │ sun safety while preventing abrupt medication stoppage. │
└──────────────────────────────┴──────────────────┴───────────────────────────────────────────────────────────┘
Post-Marketing Surveillance & Dermatologic Registry Protocols
To bridge evidence gaps regarding secondary cutaneous malignancies in solid organ transplant recipients, transplant programs and academic medical centers maintain longitudinal dermatologic surveillance workflows — structured annual skin exams, lesion-tracking photography, and shared registries linking immunosuppression exposure to tumor histology and recurrence. Pharmacovigilance teams should watch two adjacent evidence streams:
- Photoprotection and chemoprevention research: Investigating whether topical DNA repair enzyme formulations (such as liposomal T4 endonuclease V) or systemic agents can reduce new non-melanoma skin cancer incidence. The ONTRAC randomized trial (Chen et al., New England Journal of Medicine, 2015) demonstrated that oral nicotinamide 500 mg twice daily reduced the rate of new non-melanoma skin cancers by 23% in high-risk patients — an evidence-backed adjunct worth knowing about for individuals on long-term photosensitizing or immunosuppressive therapy.
Strategic Summary: Balancing Hazard Science with Clinical Reality
The IARC Monograph Volume 137 designation reflects rigorous hazard identification, but it must not be conflated with actionable regulatory bans or irrational formulary restrictions. By maintaining access to affordable generic medicines, implementing smart EHR-driven photoprotective counseling, and reserving targeted therapeutic substitutions for high-risk clinical phenotypes, biopharma leaders, health systems, and P&T committees can successfully harmonize toxicology science with real-world patient safety.
Ultimately, effective healthcare delivery requires managing known biological hazards through disciplined clinical risk mitigation rather than abandoning indispensable, life-saving generic therapies. Pharmacy directors and medical executives who implement proactive photoprotection protocols, structured dermatologic surveillance, and clear member communication will successfully protect patient health while preserving prudent healthcare stewardship.
Frequently Asked Questions
Is hydrochlorothiazide still safe to take after the IARC Group 1 classification?
Yes. Hydrochlorothiazide remains a cornerstone, guideline-recommended anti-hypertensive therapy proven across hundreds of randomized clinical trials to reduce fatal and non-fatal strokes, heart failure events, and cardiovascular mortality. Patients must not discontinue HCTZ without consulting their prescribing physician. The primary actionable measure is practicing routine sun protection (using broad-spectrum sunscreen with SPF 30 or higher, wearing protective clothing, and avoiding excessive midday UV exposure) and having periodic dermatologic skin examinations.
Did the FDA change the hydrochlorothiazide or tacrolimus label because of IARC?
The FDA updated hydrochlorothiazide labeling in 2020–2021 to include warnings regarding non-melanoma skin cancer based on FDA Sentinel System data, and tacrolimus has carried a Boxed Warning regarding malignancies for decades. While IARC Monograph Volume 137 reinforces the epidemiological evidence, the FDA has not issued new label revisions in response to the monograph.
Which specific cancers are linked to each drug according to IARC?
- Hydrochlorothiazide: Squamous cell carcinoma (SCC) of the skin and cancer of the lip (sufficient evidence); basal cell carcinoma and melanoma (limited evidence).
- Voriconazole: Cutaneous squamous cell carcinoma in sun-exposed areas (sufficient evidence).
- Tacrolimus: Non-Hodgkin lymphoma and post-transplant lymphoproliferative disorder (PTLD) in solid organ transplant recipients (sufficient evidence).
Should a P&T committee switch all patients from HCTZ to chlorthalidone?
No. While chlorthalidone is an effective alternative diuretic, it is not free of photosensitizing properties, carries higher risks of electrolyte imbalances (hypokalemia, hyponatremia), and costs slightly more ($0.089 vs $0.012 per tablet). Switching should be individualized based on clinical indications, blood pressure control, and patient-specific risk factors.
Are generic manufacturers legally liable for cancer claims after this IARC monograph?
Under established U.S. Supreme Court precedent (PLIVA v. Mensing and Mutual Pharmaceutical v. Bartlett), generic manufacturers are protected from state failure-to-warn lawsuits by federal preemption because they are legally bound to match FDA-approved Reference Listed Drug (RLD) labeling and cannot independently rewrite warnings.
Sources
- International Agency for Research on Cancer (IARC). IARC Monographs Volume 137: Hydrochlorothiazide, Voriconazole, and Tacrolimus. World Health Organization, published online February 11, 2026. Available at: monographs.iarc.who.int.
- Cogliano VJ, Corsini E, Fournier A, Nelson HH, Sergi CM, et al. Carcinogenicity of hydrochlorothiazide, voriconazole, and tacrolimus. The Lancet Oncology, 2024; 26(1):15-16 (published online November 29, 2024). Available at: pmc.ncbi.nlm.nih.gov.
- International Agency for Research on Cancer (IARC). IARC Monographs evaluation of the carcinogenicity of hydrochlorothiazide, voriconazole, and tacrolimus (evaluation summary). Available at: iarc.who.int.
- Pedersen SA, Johannesen AR, Pottegård A, et al. Hydrochlorothiazide use and risk of nonmelanoma skin cancer: a nationwide case-control study from Denmark. Journal of the American Academy of Dermatology, 2018; 78(4):673-681. Available at: jaad.org.
- Pottegård A, et al. Hydrochlorothiazide use is strongly associated with risk of lip cancer: a nationwide case-control study from Denmark. Journal of Internal Medicine, 2017; 282(4):308-318. Available at: onlinelibrary.wiley.com.
- Singer JP, et al. High cumulative dose exposure to voriconazole and risk of cutaneous squamous cell carcinoma in lung transplant recipients. American Journal of Transplantation, 2012. Available at: pubmed.ncbi.nlm.nih.gov.
- O'Neill B. Hydrochlorothiazide and squamous cell carcinoma. Current Oncology, 2020 (PMC7021350). Available at: pmc.ncbi.nlm.nih.gov.
- MDedge Cardiology News. FDA updates hydrochlorothiazide label to include nonmelanoma skin cancer risk. Available at: mdedge.com.
- European Medicines Agency (EMA). PRAC conclusion of the review of hydrochlorothiazide-containing medicines (SmPC update for non-melanoma skin cancer risk). Available at: ema.europa.eu.
- Centers for Medicare & Medicaid Services (CMS). National Average Drug Acquisition Cost (NADAC) Pricing Database, 2026-07-24 Snapshot. Available at: data.medicaid.gov.
- ClinCalc DrugStats. Hydrochlorothiazide — Drug Usage Statistics (United States, 2024 MEPS/AHRQ Data). Available at: clincalc.com.
- U.S. Food and Drug Administration (FDA). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Exclusivity and TE Code Database for Generic Hydrochlorothiazide, Prograf, and Vfend. Available at: accessdata.fda.gov.
